Browse All
Displaying 6 - 6 of 6
Author:Wiendl, Heinz Hauser, Stephen Nicholas, Jacqueline De Seze, Jerome Meuth, Sven Giacomini, Paul Robertson, Derrick Wray, Sibyl Bhatt, Alit Hu, Xixi Fu, Haoyi Jehl, Valentine Sullivan, Roseanne Boer, Ibolya Cohen, Jeffrey Kappos, Ludwig
Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2
Topic:Multiple Sclerosis
Program Number:P9.010
Author Institution:University of Münster, Münster, Germany, Muenster, Germany UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, United States, San Francisco, CA OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL Hope Neurology MS Center, Knoxville, TN, USA, Knoxville, TN Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ Novartis Pharma A.G. Basel, Switzerland, Basel, Switzerland Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
